Funding Opportunities

Our partners' latest funding opportunities are advertised below – the most recent opportunity is at the top of the list. Please scroll down for further opportunities and note that deadlines are included in the text of the post. Click on the links in the funding announcement section at the right to find general information about funding schemes offered by each of our partner organizations.

Latest Announcements

	Topic	Funding Announcements
Normal topic NCI - Administrative Supplement Opportunity to study the impact of COVID-19 on global cancer prevention and control By Lynne Davies 3 years 9 months ago	NCI - Administrative Supplement Opportunity to study the impact of COVID-19 on global cancer prevention and control	The NCI is pleased to announce the Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control (NOT-CA-21-033). The purpose of this NOSI is to inform current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries to leverage those partnerships to conduct research on the pandemic’s impact on cancer prevention, diagnosis, treatment, and outcomes. CGH will be hosting a webinar to address frequently asked questions about this funding opportunity on Thursday, February 25, 2021 at 9:00 a.m. EST. Click here to join the webinar, or copy and paste the following link into your browser https://nih.zoomgov.com/j/1615455986?pwd=S2NlclFKNXlLWGs0bHV1aDlDa1BQZz09. We encourage you to share this information widely among your networks. If you have any questions about this NOSI, or the upcoming FAQ webinar, please do not hesitate to contact Elise Garton and Paul Pearlman. Deadline: 31 March 2021 Eligibility and Eligible Individuals (Program Director/Principal Investigator): To be eligible for an Urgent Competitive Revision or an Administrative Supplement through this NOSI and the respective FOA, applications must meet the following criteria: Administrative supplement applications are limited to currently funded projects supported by NCI. PDs/PIs must hold an active award eligible for PA-20-272 supported through NCI with sufficient time (minimum 1 year) left to complete the studies proposed after the revision/supplement has been awarded within the existing project period. The proposed project for supplemental funding is required to be within the scope of the parent award and be a logical extension of the original aims. The parent award must either already include a foreign performance site in an LMIC or the applicant must include a letter of support from an LMIC institution with the application. For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award. By Lynne Davies 3 years 9 months ago
Normal topic AIRC Start Up Grant for young investigators By Lynne Davies 3 years 9 months ago	AIRC Start Up Grant for young investigators	The AIRC Start-Up grant program is for talented young scientists with a strong commitment to cancer research, seeking the opportunity of becoming independent investigators and setting up their own lab in Italy after a successful research experience abroad. The grant amount is up to 1 million euro in 5 years. TO BE ELIGIBLE APPLICANTS, OF ANY NATIONALITY: • must not have been back in Italy for more than 12 months by the deadline; • must have at least 2 first/co-first, last/co-last, corresponding/co-corresponding primary research paper in the last 5 years; Applicants should be 35 years old or younger by the time of the submission application’s deadline. Some degree of flexibility to this age-limit is applied (provided that applicants meet the other eligibility criteria), but in case of equal merit preference will be given to younger candidates. The 2021 call is now open, click here to find out more (deadline March 5). Don’t miss this opportunity to establish a new independent laboratory in Italy! By Lynne Davies 3 years 9 months ago
Normal topic Oncology Nursing Foundation - Nurse scientist focused grant opportunities By Lynne Davies 3 years 10 months ago	Oncology Nursing Foundation - Nurse scientist focused grant opportunities	Applications are now open for the following funding schemes: Addressing Cancer Health Disparities Through Evidence-Based Cancer Nursing Research (RE42) $100,000 - deadline May 17, 2021 Purpose: To support oncology nursing research addressing cancer health disparities, including in the topic areas of breast, colorectal, lung or prostate cancer. Addressing the Adverse Effects of Immunotherapy and Emerging Therapies on Cancer Patients (RE43) $150,000 - deadline May 17, 2021 Purpose: To support oncology nursing research in symptom science addressing the adverse effects of immunotherapy and emerging therapies used in the treatment of cancer patients. Symptom Science in immunotherapy and emerging therapies has been identified as one of the top cancer nursing research priorities in need of new knowledge Eligibility: The principal investigator must be a registered nurse actively involved in some aspect of cancer patient care, education or research and be PhD or DNSc prepared that has received and completed at least one research study of at least $50,000 as PI. Membership in ONS is not required. Open to international applicants. For full details, visit: https://www.onfgivesback.org/funding-for-nurses/research/research-grant By Lynne Davies 3 years 10 months ago
Normal topic General Research Grant- Open Topic in Cancer Nursing Science (RE02) By Lynne Davies 3 years 10 months ago	General Research Grant- Open Topic in Cancer Nursing Science (RE02)	The Oncology Nursing Foundation is pleased to announce that the General Research Grant is now open. For further information please visit the ONF website Letters of Intent (RE02) Due: April 15, 2021 (Separate Application) LOI acceptance notifications: May 3rd, 2021 Upon LOI acceptance, Research Grant Application Due: June 8th, 2021 Funding Level: $50,000 over 2 years Funding Available: August/September 2021 Purpose of Grant: To support rigorous scientific oncology nursing research. Research projects may include investigator-initiated research, pilot or feasibility studies, supplements to current funded projects, or developing a new aspect of a program of research. Funding preference is given to projects that involve nurses in the design and conduct of the research activity and that promote theoretically based oncology practice. Competitive applications will addresses the ONS Research Agenda See "Research Agenda of the Oncology Nursing Society: 2019-2022," published in the Oncology Nursing Forum, November 2019, Volume 46, No. 6. The following three (3) key areas in need of oncology nursing research articulated in the ONS Research Agenda are: • Symptom Science in Immunotherapy and Emerging Therapies in Precision Health and Biosignatures • Health Disparities • Palliative and Psychosocial Oncology Care Eligibility: The principal investigator (individual primarily responsible for implementing the proposal and reporting to Oncology Nursing Foundation) must be a registered nurse actively involved in some aspect of cancer patient care, education, or research and be PhD or DNSc prepared (only one PI can appear on the grant). The application is open to international applicants. By Lynne Davies 3 years 10 months ago
Normal topic Request for Application - Evolutionary Therapy (Trials) - Deadline LOI 1 March 2021 By Gauthier Bouche 4 years ago	Request for Application - Evolutionary Therapy (Trials) - Deadline LOI 1 March 2021	Opportunity open to applicants from all countries. Please read the eligibility criteria & instructions carefully before applying: https://www.anticancerfund.org/en/evolutionary-therapy This Request for Application (RFA) seeks to increase clinical trial activity of evolutionarily informed therapeutic strategies aiming at improving survival outcomes of cancer patients. Knowledge about tumour evolutionary dynamics has been growing rapidly. However, there has been a limited translation of that knowledge into therapeutic trials. The most clinically advanced strategy is adaptive therapy. Adaptive therapy is a treatment strategy attempting to prolong response to treatment by delaying the emergence of resistance. The goal of adaptive therapy is to maintain a controllable stable tumour burden by allowing a significant population of treatment-sensitive cells to survive. The main principle of the intervention is to control the tumour and prolong survival by allowing on/off treatment periods based on a valid marker. This RFA will accept clinical trials on adaptive therapy and any other evolutionarily informed strategy, as long as they meet all criteria (see eligibility criteria). We encourage investigators working on evolutionarily informed strategies (including adaptive therapy) to apply for funding for their clinical trial evaluating such approach in cancer patients. For further information on what is seen as evolutionarily informed strategies and adaptive therapy, we would like to refer applicants to a recent article by Gatenby & Brown (Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol 2020; 17: 675–86). Please contact apply@anticancerfund.org for any questions related to the RFA and to check eligibility of their proposal in case of doubt. By Gauthier Bouche 4 years ago
Normal topic American Society for Radiation Oncology call for grant and fellowship applications By Lynne Davies 4 years ago	American Society for Radiation Oncology call for grant and fellowship applications	The American Society for Radiation Oncology (ASTRO) is accepting applications from U.S. based early career scientists for the 2021 Grants and Fellowships Program. ASTRO is offering residents/fellows seed grants and career development awards to support novel research projects and foster the intellectual research talent currently entering the field of radiation oncology. ASTRO has also partnered with companies to offer ASTRO - Industry Radiation Oncology Research Training Fellowships that provide unique research training opportunities for U.S. based residents to work directly in the industry setting for up to one year. Please visit www.astro.org/fundingopps for more information. To apply and find the detailed Program Announcements please visit ProposalCentral. Eligibility: U.S. based early career scientists The fellowships deadline is January 8, 2021 and grants deadline is February 26, 2021 For questions please email science@astro.org By Lynne Davies 4 years ago
Normal topic Cancer Grand Challenge: deadline 22 April 2021 By Lynne Davies 4 years 1 month ago	Cancer Grand Challenge: deadline 22 April 2021	Cancer Research UK and the US National Cancer Institute have united to define a new era in cancer research and discovery: Cancer Grand Challenges: Dare to take on some of the most complex challenges in cancer   Cancer Grand Challenges is a global funding platform founded by Cancer Research UK and the National Cancer Institute. Through a series of £20m ($25m) awards, Cancer Grand Challenges is giving international teams of researchers the freedom to think differently, act creatively and explore truly innovative science to take on complex questions in cancer.  Nine new challenges to the international research community are now open for applications.   Call closes: 22 April 2021  Cancer Grand Challenges news and updates – follow the team on Twitter and LinkedIn By Lynne Davies 4 years 1 month ago
Normal topic World Cancer Research Fund International call for grant applications By Lynne Davies 4 years 2 months ago	World Cancer Research Fund International call for grant applications	World Cancer Research Fund International (WCRF International) is now accepting grant applications for research on the links between diet, nutrition (including body composition) and physical activity and cancer, as part of its Regular Grant Programme 2020/2021 cycle. Please pass this information on to colleagues who might be interested in applying. Visit https://www.wcrf.org/int/research-we-fund/grant-programmes/apply-research-grant for more information. Applications are accepted from principal investigators based at institutions in any country outside the Americas (North America, Central America and the Caribbean, and South America). Applications from the Americas can be submitted to the American Institute for Cancer Research at www.aicr.org. Applications from an eligible principal investigator with co-applicants/collaborators from anywhere in the world are welcome. Only applications that meet the eligibility criteria and adhere to WCRF's research principles and themes will be considered. Please note the grant programme’s scope has been updated: applicants are encouraged to read the application guidelines carefully before applying (link to guidelines PDF: https://www.wcrf.org/sites/default/files/Grants%20Guidelines%202019%20WEB_0.pdf). The deadline for applications is 16th November 2020. Any questions can be emailed to research@wcrf.org, but please refer to the FAQs and guidelines document in the first instance. By Lynne Davies 4 years 2 months ago
Normal topic Funding new arms of multi-arm trials for rare cancers By Gauthier Bouche 4 years 11 months ago	Funding new arms of multi-arm trials for rare cancers	We, the Anticancer Fund, a Belgian non-profit organization with an international scope, have joined forces with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a Swiss-based non-profit organization, for a unique opportunity to support high quality clinical trials focusing on drug repurposing and therapy optimization, with special interest in the following areas: Rare cancers (<6/100,000) ‘Financial orphan’ drugs (commercially neglected drugs) Off patent drugs Prognostic and/or predictive biomarkers We call upon all investigators to submit proposals, where funding is required to initiate a new arm of an existing multi-arm trial. Requirements include having a strong rationale with rigorous and compelling supportive data, in addition to a detailed statistical design and methodology. Amount available for this call for proposals will be at least US$ 3 million. The amount allocated per grant will depend on the number of proposals selected for funding. Application Deadline is February 28, 2020 All information can be found here: https://www.anticancerfund.org/sites/default/files/attachments/flyer_rtfccr-acf_rfp_2020_final.pdf Please share this information with anyone potentially interested and/or retweet to spread the news: https://twitter.com/Simple_Trials/status/1206988000418238464 By Gauthier Bouche 4 years 11 months ago
Normal topic Request for Applications - Trials in curative setting - International - Deadline 16 June 2019 By Gauthier Bouche 5 years 7 months ago	Request for Applications - Trials in curative setting - International - Deadline 16 June 2019	We are seeking to support clinical trials aiming at reducing recurrence rates for cancer patients treated with curative intent. The focus is on cancer types (or well-defined sub-types), with high rates of recurrence despite curative-intent treatments. The funding can go to - A new trial - A new arm in an existing multi-arm trial - Participation of an additional country in an existing international trial - Extra-funding for an under-funded existing trial You will find all details and eligibility criteria here: https://www.anticancerfund.org/en/apply-funding Feel free to retweet the following tweet to inform your network about this opportunity: https://twitter.com/Simple_Trials/status/1112681530437132288 By Gauthier Bouche 5 years 7 months ago

Funding Announcements & Feeds

Links to pages giving our partners' general funding announcements for cancer researchers are included below, where available. Organizations are listed alphabetically. Where an organization has a specific focus that is not evident from the name, this is noted in brackets after the name. Organizations marked (CC) have a specific focus on childhood cancer. If you have any questions, please contact us.

Australia

Belgium

Anticancer Fund

Canada

France

Italy

Fondazione AIRC

Japan

Japan Agency for Medical Research and Development (AMED)

Netherlands

Dutch Cancer Society (KWF)

South Africa

Cancer Association of South Africa

Spain

Spanish Association Against Cancer (AECC)

Switzerland

Rising Tide Foundation for Clinical Cancer Research

USA

Single-funder organizations
Partner	Caveat
ACS	Dollar amounts found in the ICRP database are different than what is reported in the American Cancer Society's Annual Report. The dollar amounts spent on research reported in audited reports include operating expenses of the Research Department. Additionally, the dollar amounts also exclude all grants that were cancelled after being awarded, but include money that was returned from grants cancelled in the current year that were awarded in previous years. The dollar amounts reported in the database are unaudited and include grants awarded each fiscal year, exclusive of grants that cancelled before activation.
CBCRP	The California Breast Cancer Research Program grants are awarded only to individuals or institutions in California. Grants to the University of California receive only direct funds, while grants to other institutions also receive indirect costs (overhead) at 25% or the federally negotiated rate. Collaborative awards are counted in graphs and tables by the number of co-Principal Investigators rather than the number of projects.
Komen	Dollar amounts found in the ICRP database are different than what is reported on Komen\'s website or in Komen\'s Annual Report for the following reasons: Komen commits all funds necessary to support a research grant in the year it is awarded. Therefore, Komen\'s website reports on the full amount of each grant in the year it is initiated, while the ICRP data is annualized, as described. Komen funds research grants to our Scientific Advisors (Scientific Advisory Board members and Komen Scholars) and also provides discretionary funding of research-related projects that are not traditional research grants (e.g. support of the Komen Tissue Bank, ASCO and AACR meeting support). These are included in the overall Research Program spending, as reported in our Annual Report and on our website, but are not included in the ICRP database.
NIH	NIH projects in NIH Reporter assigned to the Spend Category ‘cancer’ are included in the ICRP database from FY2005 onwards. A small number of projects are excluded if essential information is missing (primarily Project title, Institution). Previous years’ data were drawn from the NFRP and may be incomplete. Starting in FY2007 NCI reports funding supplements, etc., for each grant separately instead of including them in the main project, therefore the number of projects may differ significantly from those of previous years. Projects with a cost of $0 include those that were a no-cost extension of the grant or when funding was provided by another NIH institute or center for that FY. NCI dollars in the ICRP database are drawn from NIH reporter and may not match dollars from other NCI-only databases.
Worldwide Cancer Research	Worldwide Cancer Research is unique in that the majority of our funding is awarded to researchers in countries outside the UK. Like many UK research charities, Worldwide Cancer Research only funds the direct costs of research. This creates significant problems in making quantitative comparisons between our funding and that provided by some of the other agencies in the ICRP, which fund both the direct and indirect costs (often called overheads) of research.

UK Organizations that are part of NCRI
Partner	Caveat
NCRI (GENERIC)	NCRI submits data to ICRP on behalf of all UK NCRI members from its Cancer Research Database (CaRD). The database only includes entries where funding can be directly attributed to a set of clearly defined research objectives. This means that the CaRD only contains information on all direct research funding (project, programme, fellowship, unit and institute) financed by NCRI Member organizations, for which an abstract has been submitted and where the project is active in any given financial year (April - March). Examples of funding that are currently outside the scope of CaRD are infrastructure, meeting grants and research management support."
Breakthrough (UK)	The ICRP database includes all Breakthrough Breast Cancer\'s research spend reported through its Annual Reports & Accounts. There is some variance due to different reporting periods (1 April snapshot versus full financial year) meaning that some research spend that is already committed may not be included in the ICRP figures. Expenditure on non-research charitable activities and management support costs are excluded from the NCRI, and by extension, the ICRP dataset. For further information on Breakthrough\'s research please visit www.breakthroughresearch.org.uk or email research@breakthrough.org.uk
CR-UK (UK)	The ICRP database includes around 70% of Cancer Research UK\'s direct research spend per financial year as reported through its Annual Reports & Accounts. There is some variance due to different reporting periods meaning that some direct research spend that is planned for allocation will not be included in the ICRP figures. Expenditure on vital research services, technology transfer, meeting grants, research management support and infrastructure to support Cancer Research UK\'s activities is excluded from the NCRI, and by extension, the ICRP dataset.
Department of Health (UK)	There will always be some variance between the figures available on ICRP and the figures reported publicly by DH. There are two reasons for this. Firstly, there is variance due to different reporting periods (1 April snapshot of ICRP versus full financial year reporting by DH). Secondly, the Department\'s National Institute for Health Research (NIHR) encompasses various expenditure on NHS infrastructure for research relevant to cancer that is not in a format that it is possible to capture for ICRP.
Macmillan (UK)	The ICRP database represents about 90% of Macmillan Cancer Support\'s direct research spend per financial year. There is some variance due to different reporting periods meaning that some direct research spend that is planned for allocation will not be included in the ICRP figures. Expenditure on research management support and infrastructure to support Macmillan Cancer Support\'s activities is excluded from the NCRI, and by extension, the ICRP dataset.
Scottish Government Health Directorates (UK)	Scottish Government is committed to improve the health of the Scottish population and the Chief Scientist\'s Office (CSO) funds across a broad range of relevant disease areas. Overall, 75% of the CSO spend is committed to research infrastructure in NHS Scotland. This and much other research expenditure is therefore outside the NCRI remit and, by extension, the ICRP dataset.

Canadian organizations who are part of the CCRA
Partner	Caveat
CCRA	Caveats/limitations specific to Canadian Cancer Research Alliance organizations can be accessed here.

Difference	Detail	Impact on investment figures
Not all CCRS participating organizations are included in the ICRP.	For the period 2005–2021, CCRA submitted data to the ICRP for 35 organizations and three now defunct multi-funded initiatives (CBCRA, CPCRI, and CTCRI). Note that the Canadian Breast Cancer Research Foundation merged operations with the Canadian Cancer Society in February 2017 and Prostate Cancer Canada merged in 2020. Importantly, Alberta Innovates did not report any research projects for 2020 and 2021 due to staffing constraints. Projects within the CCRS total 30,218, of which 24,129 were reported to ICRP.	Moderate for years 2020 and 2021
Not all CCRS projects are included in the ICRP.	“Related support” grants (i.e., travel awards, workshops/symposia, LOIs, etc.) are not submitted to ICRP, but are included in reports released by CCRA. In addition, equipment/infrastructure grants through the Canada Foundation for Innovation and for other funders where the cancer relevance weighting is less than 80% are not reported to the ICRP, but are included in CCRA reports. Any project with cancer relevance of less than 20% is also not reported to the ICRP.	Moderate
Co-funded projects are listed by the administering organization.	Projects that are co-funded appear under the administering organization and are not duplicated per funder. Within CCRA reports, however, investments are reported by the actual funders.	Minor
ICRP uses a different approach to calculating annual project investment.	CCRA provides ICRP with the project budget (adjusted for cancer relevance) and start and end dates. A pro-rated calculation is used to derive annual investment. Within the CCRS, prorated calculations on the basis of annual project amounts (where those data are available) are used to calculate the annual investment.	Minor
ICRP uses different site coding conventions.	The cancer site/type codes used within the CCRS are different from ICRP site codes so results by site will vary in some instances.	Minor
ICRP has technical limitations.	ICRP has a technical limit of 12 site codes and 8 CSO codes and this requires truncation for a couple of large-scale projects within the CCRS.	Very minor
CCRA provides less descriptive information about its projects to ICRP.	Lay abstracts are submitted by CCRA to the ICRP in lieu of technical abstracts and in their language of origin. For projects without lay abstracts (and there are a significant number of these), only titles are provided. An English translation is provided alongside all French project titles to facilitate use of the search engine.	No impact on investment figures, but limits full functionality of search engine especially for organizations that do not collect/report lay abstracts.